FDA

Updated ET, Sat ,

The benefits of a Covid-19 vaccine for young children made by Pfizer Inc. and BioNTech SE exceed its risks, according to a panel of U.S. experts. Bloomberg's Drew Armstrong has more on "Bloomberg Markets: The Close." ...
The drugmaker has begun the process seeking approval to sell donanemab as a treatment for early-stage Alzheimer’s based on results from a midstage study. ...
Dr. David Kessler, pediatrician and chief science officer for the Biden Administration's Covid response, talks with Rachel Maddow about what it means that an FDA panel has recommended the Pfizer-BioNTech vaccine for children between the ages of five and eleven in terms of the children who will receive it and the overall fight against the spread of Covid.  ...
Dr. Eric Rubin, who sits on the Food and Drug Administration independent advisory panel, justified recommending the Pfizer COVID vaccine for young children Tuesday by deferring to potential upsides despite unknown side effects.What is the background?Nearly one year after the government approved the ... ...

( )